within Pharmacolibrary.Drugs.ATC.M;

model M05BA06_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.006,
    Cl             = 0.0013333333333333333,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009166666666666667,
    Tlag           = 600,            
    Vdp             = 0.002,
    k12             = 6.5,
    k21             = 6.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BA06_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ibandronic acid (ibandronate) is a bisphosphonate drug used primarily for the prevention and treatment of osteoporosis in postmenopausal women. It reduces bone resorption by inhibiting osteoclast-mediated bone loss. Ibandronic acid is approved for clinical use in several countries as both oral and intravenous formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy postmenopausal women after 50 mg oral dose.</p><h4>References</h4><ol><li><p>McCormack, PL, &amp; Plosker, GL (2006). Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. <i>Drugs</i> 66(5) 711–728. DOI:<a href=\"https://doi.org/10.2165/00003495-200666050-00011\">10.2165/00003495-200666050-00011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16620148/\">https://pubmed.ncbi.nlm.nih.gov/16620148</a></p></li><li><p>Filipe, A, et al., &amp; Boudreault, S (2014). Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study. <i>Drugs in R&amp;D</i> 14(2) 105–112. DOI:<a href=\"https://doi.org/10.1007/s40268-014-0044-x\">10.1007/s40268-014-0044-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24756462/\">https://pubmed.ncbi.nlm.nih.gov/24756462</a></p></li><li><p>Liberman, UA (2006). Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. <i>Drugs &amp; aging</i> 23(4) 289–298. DOI:<a href=\"https://doi.org/10.2165/00002512-200623040-00002\">10.2165/00002512-200623040-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16732688/\">https://pubmed.ncbi.nlm.nih.gov/16732688</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BA06_1;
